Literature DB >> 22035779

Soluble ST2 is a marker for acute cardiac allograft rejection.

Domingo A Pascual-Figal1, Iris P Garrido, Rosa Blanco, Alfredo Minguela, Antonio Lax, Jordi Ordoñez-Llanos, Antoni Bayes-Genis, Mariano Valdés, Stephanie A Moore, James L Januzzi.   

Abstract

BACKGROUND: Soluble ST2 (sST2), an interleukin (IL)-1 receptor family member, has a role in immunologic tolerance and has also emerged as a biomarker of cardiac stretch and remodeling. The sST2 role in heart transplantation is still unknown.
METHODS: From the heart transplantation population at our institution (n = 74), we selected a subset of 26 patients who had an acute rejection episode in the first year after transplantation (35%; 52 ± 14 years; 76% men). Endomyocardial biopsy (EMB) results obtained at the time of the first rejection episode represented the rejection cohort (n = 26). Each patient served as a control to himself or herself, with EMB without rejection obtained before and after the rejection episode (n = 52). All laboratory measurements and blood samples were obtained at the time of EMB.
RESULTS: sST2 concentrations rose significantly in the context of acute rejection (130 [60 to 238] versus 51 ng/mL [28 to 80]; p = 0.002). Tertile analyses of sST2 concentrations revealed a graded association with rejection (p = 0.002) and repeated measurement analyses showed that sST2 concentrations were significantly modulated by the presence of rejection (p = 0.001). In receiver operator characteristic (ROC) analysis, sST2 had an area under the curve (AUC) of 0.72; the optimal cutoff point was 68 ng/mL (positive predictive value of 53%, negative predictive value of 83%), which predicted acute cellular rejection (odds ratio [OR] 4.9; 95% confidence interval [CI], 1.7 to 14.5; p = 0.004). The addition of sST2 values to those for the N-terminal pro B-type natriuretic peptide (NT-proBNP) resulted in a significant improvement on the integrated discrimination index (IDI) for rejection (relative improvement of 24%; p = 0.021).
CONCLUSIONS: sST2 concentrations are modulated by the presence of acute rejection and provide complementary predictive ability to NT-proBNP for the biochemical identification of rejection.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22035779     DOI: 10.1016/j.athoracsur.2011.07.048

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

Review 1.  Interleukin-33 in health and disease.

Authors:  Foo Yew Liew; Jean-Philippe Girard; Heth Roderick Turnquist
Journal:  Nat Rev Immunol       Date:  2016-09-19       Impact factor: 53.106

2.  Computational Cosolvent Mapping Analysis Leads to Identify Salicylic Acid Analogs as Weak Inhibitors of ST2 and IL33 Binding.

Authors:  Xinrui Yuan; Krishnapriya Chinnaswamy; Jeanne A Stuckey; Chao-Yie Yang
Journal:  J Phys Chem B       Date:  2022-03-16       Impact factor: 3.466

Review 3.  Acute and chronic phagocyte determinants of cardiac allograft vasculopathy.

Authors:  Kristofor Glinton; Matthew DeBerge; Xin-Yi Yeap; Jenny Zhang; Joseph Forbess; Xunrong Luo; Edward B Thorp
Journal:  Semin Immunopathol       Date:  2018-08-23       Impact factor: 9.623

4.  From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Authors:  Abdulraouf M Ramadan; Etienne Daguindau; Jason C Rech; Krishnapriya Chinnaswamy; Jilu Zhang; Greg L Hura; Brad Griesenauer; Zachary Bolten; Aaron Robida; Martha Larsen; Jeanne A Stuckey; Chao-Yie Yang; Sophie Paczesny
Journal:  JCI Insight       Date:  2018-07-26

5.  Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection.

Authors:  L R Mathews; J M Lott; K Isse; A Lesniak; D Landsittel; A J Demetris; Y Sun; D F Mercer; S A Webber; A Zeevi; R T Fischer; B Feingold; H R Turnquist
Journal:  Am J Transplant       Date:  2015-12-11       Impact factor: 8.086

6.  ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.

Authors:  Jilu Zhang; Abdulraouf M Ramadan; Brad Griesenauer; Wei Li; Matthew J Turner; Chen Liu; Reuben Kapur; Helmut Hanenberg; Bruce R Blazar; Isao Tawara; Sophie Paczesny
Journal:  Sci Transl Med       Date:  2015-10-07       Impact factor: 17.956

7.  ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening.

Authors:  Megan Griffiths; Jun Yang; Catherine E Simpson; Dhananjay Vaidya; Melanie Nies; Stephanie Brandal; Rachel Damico; D Dunbar Ivy; Eric D Austin; Michael W Pauciulo; Katie A Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; William C Nichols; Allen D Everett
Journal:  Chest       Date:  2021-02-18       Impact factor: 10.262

8.  Role of Soluble ST2 as a Marker for Rejection after Heart Transplant.

Authors:  Ga Yeon Lee; Jin-Oh Choi; Eun-Seon Ju; Yoo-Jung Lee; Eun-Seok Jeon
Journal:  Korean Circ J       Date:  2016-11-01       Impact factor: 3.243

9.  Editorial: Danger Signals Triggering Immune Response and Inflammation.

Authors:  Abdulraouf Ramadan; Walter G Land; Sophie Paczesny
Journal:  Front Immunol       Date:  2017-08-11       Impact factor: 7.561

10.  Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis.

Authors:  Jin Wang; Mengying He; Huihui Li; Yanghui Chen; Xiang Nie; Yuanyuan Cai; Rong Xie; Lijuan Li; Peng Chen; Yang Sun; Chenze Li; Ting Yu; Houjuan Zuo; Guanglin Cui; Kun Miao; Chunxia Zhao; Jiangang Jiang; Bettina Heidecker; Olga Barnett; Alan Maisel; Chen Chen; Dao Wen Wang
Journal:  J Am Heart Assoc       Date:  2022-04-04       Impact factor: 6.106

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.